Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: Disease progression, treatment durability, and drug toxicity

Research output: Contribution to journalArticlepeer-review

Abstract

We compared clinical disease progression in 159 human immunodeficiency virus (HIV)-infected persons for whom highly active antiretroviral therapy (HAART) was initiated when they had CD4+ T lymphocyte counts of 350-499 cells/mm3 with progression in 174 HIV-infected patients for whom it was not. Disease progression did not differ between the 2 groups (P = .21, log-rank test). Fifty-three percent of the 159 treated patients had HIV type 1 RNA levels of >400 copies/mL at the most recent evaluation, and 41% had experienced adverse drug reactions necessitating a change in regimen. These findings support the recommendation that HAART not be initiated for patients with CD4+ cell counts of >350 cells/mm3.

Original languageEnglish (US)
Pages (from-to)812-815
Number of pages4
JournalClinical Infectious Diseases
Volume36
Issue number6
DOIs
StatePublished - Mar 15 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Initiation of highly active antiretroviral therapy at CD4<sup>+</sup> T lymphocyte counts of >350 cells/mm<sup>3</sup>: Disease progression, treatment durability, and drug toxicity'. Together they form a unique fingerprint.

Cite this